Methods of treating cancer in patients who have previously been exposed to immune checkpoint inhibitors.

Administering IRAK4 inhibitors or degraders to patients who have received immune checkpoint inhibitors enhances treatment efficacy for IRAK4-related cancers by increasing response rates, as seen in reduced bone marrow blasts.

JP2026519083APending Publication Date: 2026-06-11CURIS INC
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
CURIS INC
Filing Date
2024-05-31
Publication Date
2026-06-11

Smart Images

  • Figure 2026519083000058
    Figure 2026519083000058
  • Figure 2026519083000059
    Figure 2026519083000059
  • Figure 2026519083000001
    Figure 2026519083000001
Patent Text Reader

Abstract

This disclosure relates to methods for treating specific diseases and disorders (e.g., IRAK4-related diseases and disorders).
Need to check novelty before this filing date? Find Prior Art